Saliva Clinical Trials

45 recruitingLast updated: May 21, 2026

There are 45 actively recruiting saliva clinical trials across 16 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, New York, New York, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Saliva Trials at a Glance

45 actively recruiting trials for saliva are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Houston, New York, and Philadelphia. Lead sponsors running saliva studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, M.D. Anderson Cancer Center, and Mayo Clinic.

Browse saliva trials by phase

About Saliva Clinical Trials

Looking for clinical trials for Saliva? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Saliva trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Saliva clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Breast CancerUrothelial CarcinomaSoft Tissue Sarcoma+2 more
Avacta Life Sciences Ltd158 enrolled9 locationsNCT04969835
Recruiting
Not Applicable

Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity

BiomarkersOral Squamous Cell CarcinomaEpigenetics+3 more
Centre Hospitalier Universitaire, Amiens60 enrolled1 locationNCT05791149
Recruiting

Characterization of Diseases With Salivary Gland Involvement

Healthy VolunteerSjogren's SyndromeSalivary Gland Disease
National Institute of Dental and Craniofacial Research (NIDCR)1,150 enrolled1 locationNCT02327884
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1Phase 2

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Radiation-Induced Xerostomia and Hyposalivation
RiboX Therapeutics Ltd.42 enrolled4 locationsNCT06714253
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled42 locationsNCT02012699
Recruiting
Phase 2

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Metastatic Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8Stage IV Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology146 enrolled150 locationsNCT05408845
Recruiting

Oropharynx (OPX) Biomarker Trial

Head and Neck CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+8 more
Mayo Clinic560 enrolled1 locationNCT06356272
Recruiting

Discovery and Validation of Periodontitis Biomarkers

PeriodontitisBiomarker in Early DiagnosisSaliva
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University228 enrolled1 locationNCT07293481
Recruiting

The Pathogenesis and Natural History of Sjogren's Disease

Sjogren's SyndromeSalivary GlandPathogenesis
National Institute of Dental and Craniofacial Research (NIDCR)300 enrolled1 locationNCT01425892
Recruiting
Not Applicable

Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.

PainHead and Neck CancerQuality of Life+6 more
Mucosa Innovations, S.L.63 enrolled1 locationNCT05635929
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 2

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled21 locationsNCT06695845
Recruiting

The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

Head and Neck CancerSalivary Gland CancerNasopharynx Cancer+2 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano13,600 enrolled10 locationsNCT05483374
Recruiting
Phase 2

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Salivary Gland CarcinomaPrecision Therapy
Peking Union Medical College39 enrolled2 locationsNCT06145308
Recruiting
Phase 2

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

Salivary Gland Carcinomas
Ji Dongmei90 enrolled1 locationNCT07464366
Recruiting

A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma of the Salivary GlandAdenoid Cystic Carcinoma of the Head and Neck
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano114 enrolled1 locationNCT07507578
Recruiting
Phase 2

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Salivary Gland CancersGland
M.D. Anderson Cancer Center30 enrolled1 locationNCT05884320
Recruiting

Immune Biomarker Study for Salivary Gland Carcinoma

Salivary Gland TumorBenign Salivary Gland Tumor
University of Erlangen-Nürnberg Medical School300 enrolled2 locationsNCT06047236